estriol: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
estriol: clinical details
Prescribing considerations
- Confirm symptoms are compatible with postmenopausal vaginal oestrogen deficiency and assess personal and family history.
- Treat active vaginal infection and investigate unexplained genital bleeding before treatment.
- Product licences differ: Ovesse has specific age, amenorrhoea and pharmacy-supply criteria; selected prescription products also cover perioperative vaginal-surgery use.
- Routine addition of a progestogen is not recommended for these low-systemic-exposure products, but continued treatment should be reviewed.
- Use caution with endometriosis, fibroids, migraine, hypertension, diabetes, gallstones, epilepsy, asthma, systemic lupus erythematosus and cardiac, renal or liver disease.
Contraindications and cautions
- Hypersensitivity to estriol or formulation excipients
- Known, past or suspected breast cancer or another oestrogen-dependent malignancy, subject to product-specific wording
- Undiagnosed genital bleeding or untreated endometrial hyperplasia
- Previous or current venous thromboembolism, known thrombophilia, or active or recent arterial thromboembolic disease
- Acute liver disease, or previous liver disease while liver function remains abnormal
- Porphyria
- Product-specific Ovesse exclusions include current vaginal infection, severe vaginal itching, vulval rash or dermatosis, and particular histories of unopposed systemic oestrogen use
Monitoring
- Review symptom response, continued need, adherence and adverse effects periodically.
- Investigate bleeding or spotting occurring during treatment.
- Maintain usual breast screening and assess reported breast changes.
- Stop and reassess for jaundice, deteriorating liver function, marked blood-pressure increase, new migraine-type headache, pregnancy or thromboembolic symptoms.
Clinical pharmacology
Estriol is a short-acting natural oestrogen. Vaginal administration restores urogenital epithelium, microflora and physiological pH. Some systemic absorption occurs, followed by hepatic conjugation and mainly renal elimination.
Formulation and product differences
- Creams use a calibrated reusable applicator; cetyl and stearyl alcohol can cause local contact reactions.
- Pessaries are inserted with a finger and avoid applicator cleaning.
- Ovesse is a pharmacy-supplied cream with a narrower licensed population and additional screening and referral requirements.
- Selected prescription cream and pessary products are also licensed around vaginal surgery.
estriol preparations and strengths
Cream
Route: Cutaneous
Strengths: 1 mg/g, 0.01% w/w
Pessary
Route: Vaginal
Strengths: 0.03 mg, 0.5 mg
Vaginal cream
Route: Vaginal
estriol interactions
Important interactions are uncommon because systemic absorption is limited, but disclose all medicines and vaginal products.
Other locally applied vaginal treatments
Using products together may alter local absorption, tolerability or effectiveness.
Carbamazepine, phenytoin, rifampicin, rifabutin, nevirapine and efavirenz
These may increase oestrogen metabolism, potentially reducing estriol's effect or changing bleeding patterns, although relevance with vaginal use is uncertain.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.